George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004743-83/GB
Argentina
Belgium
Brazil
Canada
Chile
Colombia
France
Germany
India
Israel
Italy
Mexico
Moldova, Republic of
Netherlands
Peru
Poland
Portugal
Romania
Russian Federation
Serbia
South Africa
Spain
Turkey
Ukraine
United Kingdom
United States
Yes indeed, target reiterated following vaccine announcements, available from their website with a free account
It would be a shame if we all held on through this coordinated shorting attack just to sell up at £3
Thanks, missed this one
Watched one of his earlier pre-Covid presentations earlier, he really is quite impressive
Good idea
Hopefully see some shorts closing now, onwards and upwards.
You’re the only person who thinks that.
Has this been discussed here? Couldn’t find anything and looks very relevant.
https://www.news-medical.net/news/20201123/SARS-CoV-2-spike-deletion-mutations-may-evade-current-vaccine-candidates-study-finds.aspx
Just a warning up front to the trolls, the article contains all complicated sciencey language so you may want to ask an adult to explain it, just concentrate on these sentences as an overview:
“This virus is therefore finding niches of antigenic variation that enable it to escape neutralization by preventing the binding of the protective antibody to the altered antigen. The escape mutation is also transmitted to other individuals.”
“If vaccines are unable to induce protective immunity, the COVID-19 pandemic will slowly subside over time to become an endemic illness, such as influenza. This latter family of viruses has shown the same pattern at least four times over the last 100 years”
This is part of the problem we face, with all he media hype and desperate search for good news, there are people who genuinely believe Covid will be over by May. Even though there is no evidence to support it, people will believe it.
What is quite enjoyable is knowing that once filtered, they have no way of responding. It’s like we’re standing on a plinth with a loud hailer and they’re down in the crowd, muted by means of a pulp fiction style ball gag.
It amuses me that there are a billion people using the internet and these individuals have opted to occupy the very bottom of the social hierarchy - the troll. Filtered by many, despised by all, internet trolling is an unusual choice for any human looking to interact with others, to actually spend time trying to disrupt useful discussion among adults says something about their psychological state. I hope for their sakes that these are online personas that they’ve adopted rather than a snapshot of their real life qualities, if not it’s a sad waste of a life.
Oops missed the last para:
Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pension.
The advent of three viable coronavirus vaccines is great news – unless, like London-quoted Synairgen, you make treatments for the disease.
On Nov 9, when the success of the Pfizer/ BioNTech vaccine was announced, shares in the firm fell by 39pc. They had jumped more than fivefold on July 20, when the success of its own treatment for Covid-19 in hospital trials was reported.
It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months, there will be far fewer people admitted to hospital with the disease and much less need for treatments.
That may be true. But the success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so.
This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker.
I don’t subscribe but your link takes me straight past the paywall.
Haha, love this thread
I nearly fell off my sofa at the end when he hinted at 3 billion revenue, backed up with a solid need for government stockpiling for future outbreaks. I can’t see much downside here at all, if phase 3 confirms what seem to be pretty resilient phase 2 results, he’s CEO of a company that owns a golden goose.
I think he said they’re looking to take it to market themselves for the Covid treatment as they’ve done the bulk of the work and it’s easy to sell for stockpiling purposes with minimal need for salespeople, major pharma partnership is something to consider later for copd, asthma etc. Later in his view starts Q2 2021 and could stretch for another year as they negotiate with big pharma, in the meantime they’re selling SNG001 themselves to an easy market.
Did I hear that correctly?